228 related articles for article (PubMed ID: 31587791)
1. Role of Cardiovascular Biomarkers in the Risk Stratification, Monitoring, and Management of Patients with Cancer.
Hoeger CW; Hayek SS
Cardiol Clin; 2019 Nov; 37(4):505-523. PubMed ID: 31587791
[TBL] [Abstract][Full Text] [Related]
2. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients.
Tajiri K; Aonuma K; Sekine I
Jpn J Clin Oncol; 2017 Aug; 47(8):678-682. PubMed ID: 28505345
[TBL] [Abstract][Full Text] [Related]
3. Roadmap for biomarkers of cancer therapy cardiotoxicity.
Yu AF; Ky B
Heart; 2016 Mar; 102(6):425-30. PubMed ID: 26674989
[TBL] [Abstract][Full Text] [Related]
4. The Role of Biomarkers to Evaluate Cardiotoxicity.
Upshaw JN
Curr Treat Options Oncol; 2020 Aug; 21(10):79. PubMed ID: 32767198
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond.
Attanasio U; Di Sarro E; Tricarico L; Di Lisi D; Armentaro G; Miceli S; Fioretti F; Deidda M; Correale M; Novo G; Sciacqua A; Nodari S; Cadeddu C; Tocchetti CG; Palazzuoli A; Mercurio V
Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397436
[TBL] [Abstract][Full Text] [Related]
6. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
Pudil R; Mueller C; Čelutkienė J; Henriksen PA; Lenihan D; Dent S; Barac A; Stanway S; Moslehi J; Suter TM; Ky B; Štěrba M; Cardinale D; Cohen-Solal A; Tocchetti CG; Farmakis D; Bergler-Klein J; Anker MS; Von Haehling S; Belenkov Y; Iakobishvili Z; Maack C; Ciardiello F; Ruschitzka F; Coats AJS; Seferovic P; Lainscak M; Piepoli MF; Chioncel O; Bax J; Hulot JS; Skouri H; Hägler-Laube ES; Asteggiano R; Fernandez TL; de Boer RA; Lyon AR
Eur J Heart Fail; 2020 Nov; 22(11):1966-1983. PubMed ID: 33006257
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
de Vries Schultink AHM; Boekhout AH; Gietema JA; Burylo AM; Dorlo TPC; van Hasselt JGC; Schellens JHM; Huitema ADR
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):431-442. PubMed ID: 29429038
[TBL] [Abstract][Full Text] [Related]
8. Biomarker Discovery in Cardio-Oncology.
Vohra A; Asnani A
Curr Cardiol Rep; 2018 May; 20(7):52. PubMed ID: 29802472
[TBL] [Abstract][Full Text] [Related]
9. Cardio-oncological management of patients.
Cardinale DM; Barac A; Torbicki A; Khandheria BK; Lenihan D; Minotti G
Semin Oncol; 2019 Dec; 46(6):408-413. PubMed ID: 31784042
[TBL] [Abstract][Full Text] [Related]
10. [Cardiotoxicity of anticancer therapies. Towards the implementation of cardio-oncology units].
Hameau R; Gabrielli L; Garrido M; Guzmán AM; Retamal I; Vacarezza MJ; Greig D; Ocqueteau M; Sánchez C; Pizarro M; Corvalán A; Lavandero S; Castro PF; Martínez G
Rev Med Chil; 2018 Jan; 146(1):68-77. PubMed ID: 29806680
[TBL] [Abstract][Full Text] [Related]
11. Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention.
Narayan V; Ky B
Annu Rev Med; 2018 Jan; 69():97-111. PubMed ID: 29414258
[TBL] [Abstract][Full Text] [Related]
12. Current and emerging modalities for detection of cardiotoxicity in cardio-oncology.
Khouri MG; Klein MR; Velazquez EJ; Jones LW
Future Cardiol; 2015 Jul; 11(4):471-84. PubMed ID: 26235924
[TBL] [Abstract][Full Text] [Related]
13. [Troponin I and B-type Natriuretic Peptide (BNP) as biomarkers for the prediction of cardiotoxicity in patients with breast cancer treated with adjuvant anthracyclines and trastuzumab].
Pistillucci G; Ciorra AA; Sciacca V; Raponi M; Rossi R; Veltri E
Clin Ter; 2015; 166(1):e67-71. PubMed ID: 25756270
[TBL] [Abstract][Full Text] [Related]
14. Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity.
Germanakis I; Anagnostatou N; Kalmanti M
Pediatr Blood Cancer; 2008 Sep; 51(3):327-33. PubMed ID: 18523992
[TBL] [Abstract][Full Text] [Related]
15. The Role of Biomarkers in Detection of Cardio-toxicity.
Shah KS; Yang EH; Maisel AS; Fonarow GC
Curr Oncol Rep; 2017 Jun; 19(6):42. PubMed ID: 28421484
[TBL] [Abstract][Full Text] [Related]
16. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.
Rygiel K
Indian J Pharmacol; 2016; 48(5):490-497. PubMed ID: 27721532
[TBL] [Abstract][Full Text] [Related]
17. Can cardio-oncology deliver better care internationally?
Iakobishvili Z; Kornowski R
Future Oncol; 2015; 11(16):2259-62. PubMed ID: 26260804
[No Abstract] [Full Text] [Related]
18. Recent Advances in Serum Biomarkers for Risk Stratification and Patient Management in Cardio-Oncology.
Joolharzadeh P; Rodriguez M; Zaghlol R; Pedersen LN; Jimenez J; Bergom C; Mitchell JD
Curr Cardiol Rep; 2023 Mar; 25(3):133-146. PubMed ID: 36790618
[TBL] [Abstract][Full Text] [Related]
19. Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.
Gulati G; Heck SL; Røsjø H; Ree AH; Hoffmann P; Hagve TA; Norseth J; Gravdehaug B; Steine K; Geisler J; Omland T
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29118031
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Toxicities in Pediatric Cancer Survivors.
Ryan TD; Nagarajan R; Godown J
Cardiol Clin; 2019 Nov; 37(4):533-544. PubMed ID: 31587793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
